StreetInsider.com News Articles

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Tue, 01 Sep 2026 08:30:00 -0400

Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping

THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark.

The accepted abstracts, both presented by Dr. Robert Schwartz of Autonomix, highlight the potential of the Company’s

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Tue, 01 Sep 2026 08:30:00 -0400

Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping

The accepted abstracts, both presented by Dr. Robert Schwartz of Autonomix, highlight the potential of the Company’s

Form 8-K Autonomix Medical, Inc. For: Aug 24

Wed, 26 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26982714.html

Form 8-K Autonomix Medical, Inc. For: Aug 24

Wed, 26 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26982714.html

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Wed, 26 Aug 2026 08:30:00 -0400

New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain

THE WOODLANDS, TX, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office (USPTO), titled “Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development” on August 25, 2026.

The newly issued patent

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Wed, 26 Aug 2026 08:30:00 -0400

The newly issued patent

Autonomix Medical raises $4.9M via warrant inducement agreement

Tue, 25 Aug 2026 07:25:08 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants originally issued on July 15, 2026.

Under the agreement, the investor will exercise warrants to purchase 857,462 shares of common stock at $5.75 per share. Gross proceeds are expected to total approximately $4.9 million, before financial advisory fees and offering expenses. The transaction is expected to close on or about August 26, 2026, subject to customary closing conditions.

In exchange for the immediate cash exercise of the existing warrants, Autonomix agreed to issue new unregistered Series E-1 and Series E-2 warrants, each

Autonomix Medical raises $4.9M via warrant inducement agreement

Tue, 25 Aug 2026 07:25:08 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants originally issued on July 15, 2026.

In exchange for the immediate cash exercise of the existing warrants, Autonomix agreed to issue new unregistered Series E-1 and Series E-2 warrants, each

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Mon, 24 Aug 2026 21:06:00 -0400

THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75.

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Mon, 24 Aug 2026 21:06:00 -0400

Form 10-Q Autonomix Medical, Inc. For: Jun 30

Thu, 13 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26915577.html

Form 10-Q Autonomix Medical, Inc. For: Jun 30

Thu, 13 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26915577.html

Autonomix Medical completes GLP preclinical study ahead of FDA submission

Wed, 12 Aug 2026 08:16:14 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced the completion of its Good Laboratory Practice (GLP) preclinical study, a step the company said supports its planned submission to the U.S. Food and Drug Administration.

The study evaluated the safety, functionality, and performance of the Autonomix platform across multiple anatomical targets using porcine models, in accordance with FDA GLP standards. Final histopathology and laboratory analyses confirmed the safety and performance outcomes the company had previously reported.

"The final pathology and laboratory findings reinforce the positive safety and performance profile we have observed throughout the study and provide important validation of our platform," said Brad Hauser,

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Wed, 12 Aug 2026 08:15:00 -0400

Final histology and laboratory analyses support the study’s safety and performance objectives

THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA).

The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Wed, 12 Aug 2026 08:15:00 -0400

Final histology and laboratory analyses support the study’s safety and performance objectives

The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically

Autonomix Medical CMO to receive CTF lifetime achievement award

Mon, 10 Aug 2026 08:20:14 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced that its co-founder and Chief Medical Officer, Robert Schwartz, M.D., has been named the recipient of the 2026 Cardiovascular Tech Forum Lifetime Achievement Award.

Dr. Schwartz is scheduled to be honored at Octane's 2026 Cardiovascular Tech Forum on September 18, 2026, in Newport Beach, California. The annual award recognizes individuals for contributions to cardiovascular technology through scientific achievement, clinical innovation and entrepreneurial leadership.

According to the company's press release, Dr. Schwartz has authored more than 500 scientific publications and holds more than 200 patents. He has also founded multiple medical technology companies, including co-inventing the Watchman

Autonomix Medical CMO to receive CTF lifetime achievement award

Mon, 10 Aug 2026 08:20:14 -0400

Autonomix Medical CMO receives 2026 CTF Lifetime Achievement Award

Mon, 10 Aug 2026 08:20:13 -0400

Dr. Schwartz will be honored at Octane's 2026 Cardiovascular Tech Forum on September 18, 2026, in Newport Beach, California. The annual award recognizes individuals for contributions to cardiovascular technology through scientific achievement, clinical innovation, and entrepreneurial leadership.

During his career, Dr. Schwartz has authored more than 500 scientific publications and holds more than 200 patents. He has founded multiple medical technology companies, including co-inventing the Watchman device, which was later acquired by

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Mon, 10 Aug 2026 08:20:00 -0400